Home›Companies›Biotech & Pharma›Omniox

Omniox, Inc.

Develops oxygen-delivery therapies for patients with diseases involving low tissue oxygen.

Updated Nov 10, 2026·Latest SEC filing Mar 30, 2026·Suggest an edit

About Omniox

Omniox is a private company based in San Francisco, California. It has reported $39,423,963 raised in five offerings on Form D since July 2012. Its chief executive is Jonathan Winger.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 1, 2016Mar 30, 2026$24,066,235of $28.0M target93$258KDebtRule 506(b)Form D ↗
Jul 12, 2016Jul 27, 2016$4,708,814of $8.5M target29$162KEquity, Debt, Securities on exerciseRule 506(b)Form D ↗
Jun 6, 2014Jun 18, 2014$6,603,710fully sold21$314KEquityRule 506(b)Form D ↗
Jun 17, 2013Aug 6, 2013$3,043,754of $3.3M target17$179KEquity, Options, Securities on exercise06Form D ↗
Jun 29, 2012Jul 6, 2012$1,001,450of $7.5M target20$50,073Equity, Options, Securities on exercise06Form D ↗
Total, five offerings$39,423,963

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Omniox's Form D filed Mar 30, 2026.

JS
LM
Laurence Marton
Director
Also a director at Matternet.
MM
Jonathan Winger
Jonathan Winger
Co-Founder and CEO, director

Earlier filings also listed Stephen Cary (executive officer and director, last listed Jul 2016), John Wesley (director, last listed Jul 2016) and Ajit Shah (director, last listed Jul 2016).

Sources

  1. SECOmniox, Inc. filing history
  2. CompanyOmniox management